Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"Maintenance therapy"”.
-
Comparative Long-term Outcomes of Detoxification and Opioid Maintenance Therapy for the Management of Opioid Dependence
… to illicit opioids detoxification and opioid maintenance therapy (OMT) are the primary treatment options. Over the past decade the United Kingdom has seen a mostly political push towards a more abstinence-oriented treatment agenda and away from the prevailing approach of ‘harm reduction’, …
-
Immune parameters as predictors of response to maintenance therapy in low grade non-Hodgkin's lymphoma patients
… Most LG-NHL patients respond well to chemotherapy, but are rarely cured, making death from LG-NHL virtually inevitable. In this study on LG-NHL patients, all patients received combination chemotherapy for 6 weeks, which consisted of cyclophosphamide, oncovin (vincristine) and prednisone …
-
Leveraging copper chelators as targeted therapy for BRAFV600E mutant thyroid cancer
… with surgical resection and radioiodine therapy, survival drops precipitously in metastatic or radioiodine-resistant disease. 60% of papillary thyroid cancers (PTC) have an oncogenic V600E mutation in the kinase BRAF, which leads to a constitutively active and oncogenic kinase. This …
-
B cell therapy in ANCA-associated vasculitis
… activity and the efficacy of B cell depletion therapy with rituximab as both an induction and maintenance agent. Rituximab, the only licenced therapy for AAV, is associated with a remission failure rate of 10-30%, and for those who achieve remission, repeated doses are needed to prevent …
-
The Effect of Treatment on Peri-Implant Disease Progression
… were classified as no treatment, non-surgical therapy, prophylaxis/maintenance, or surgical therapy. Statistical analysis employed chi-square testing and multivariate regression modeling using JMP Pro 17.1 software, with significance set at p<0.05. Mean follow-up was 7.8 years (range 0-20 …
-
The role of the YTHDF m6A readers in neuroblastoma
… Retinoic acid (RA) is a key agent employed in NB therapy; it induces cell differentiation limiting the proliferation of malignant cells. However, therapeutic protocols adopting RA are limited to maintenance therapy. Thereby, identifying new therapeutic strategies that synergistically enhance RA …
-
Harm reduction in the context of drug use in Malaysia, a critical analysis of its justification and its compatibility with the criminal justice approach
… drug control conventions. The Methadone Maintenance Therapy (MMT) and Needle and Syringe Exchange Programme (NSEP) harm reduction measures are further justified by their efficacy and cost-effectiveness in decreasing drug use and HIV pathogen transmission. This thesis also argues that any …
-
Donor lymphocyte infusion after allogeneic stem cell transplantation in children
… infusion (DLI) is an important curative therapy for relapse or persistence of hematologic malignancy and bone marrow failure syndrome following allogeneic hematopoietic stem cell transplantation (allo HSCT). However, DLI is limited by the development of graft-versus-host disease (GVHD)and …
-
Evaluating the Clinical and Financial Impact of Multi-Gene Panel Testing
… mutation, 5 of them (25%) had a change in therapy. All of these patients responded to the change in therapy with stable disease, and while three of them started the therapy within a month of the Foundation testing resulting, the other two waited 5 and 11 months. The fifth patient was …
-
Characterizing Effects of Sphingosine-1-Phosphate Receptor 1 Activation in Subtypes of Central Amygdala Neurons and Effects of Prenatal Methadone Exposure on Motor Cortex Neurons in Mice
… is a synthetic μ-opioid agonist used for opioid maintenance therapy and chronic pain management. Methadone treatment for opioid use disorder in pregnant women can result in structural changes within the brain of their offspring causing and developmental delays to their children, including poorer …
-
Characterizing the Activity of Three Novel Differentiation-Inducing Compounds in Neuroblastoma Cells
… minimal residual disease. Current post-remission maintenance therapy includes the use of differentiation agent 13-cis-retinoic acid. However, approximately 50% of patients treated become unresponsive to this agent. The discovery of new differentiation agents is necessary in order to treat patients …
-
Culturally Informed Motivational Interviewing to Improve Oral Chemotherapy Adherence for Pediatric Acute Lymphoblastic Leukemia Patients and Their Caregivers: A Feasibility, Acceptability, and Preliminary Efficacy Trial
BACKGROUND: Curative therapy for childhood acute lymphoblastic leukemia (ALL) mandates a two-to-three-year maintenance chemotherapy phase wherein patients must take daily oral 6-mercaptopurine (6-MP). 6-MP regimen adherence is challenging and failure to take medication has been associated with an …
-
Modelling Β2Ar Regulation
… regulatory pathways that are stimulated during therapy and bring about tachyphylaxis, which is the loss of drug effects. Thus, an understanding of how the β2AR responds to various β-agonists is crucial to their rational use. Towards that end we have developed deterministic models that explore …
-
Neuroimaging Investigation of Binge Alcohol Drinking and Opioid Dependency.
… on impulsivity in patients receiving methadone maintenance therapy suggests a benefit in reduction of methadone dose, and the finding of a negative correlation between impulsivity and compulsivity measures supports Holander and Wong’s impulsive-compulsive diathesis model. Further work to …
-
Tracking Treatment Response and Resistance to Parp Inhibition (Talazoparib) In Hereditary Pancreatic Cancer.
… for Clinical Oncology (ASCO) conference in 2019, maintenance therapy with Olaparib significantly delayed the progression of metastatic <em>BRCA</em> mutant pancreatic adenocarcinoma (PDAC) compared to placebo (7.4 months vs 3.8 months). Talazoparib, a second generation PARP inhibitor, is …